NCT06862726View on ClinicalTrials.gov

Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non Valvular Atrial Fibrillation
Interventions
DRUG

Anti Xa dosage

VKA: quadriseparable tablet Apixaban: 5 mg twice daily or 2.5 twice daily Rivaroxaban: 20 mg once a day or 15 mg once a day

DRUG

Dosage of PT-INR

This arm contain 40 pateints treated by VKA,. PT-INR dosage will be performed.

Trial Locations (1)

1006

Charles Nicolle hospital, Tunis

All Listed Sponsors
lead

Les Laboratoires des Médicaments Stériles

INDUSTRY